anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cleaning agent having high safety and stability capable of exhibiting excellent lipstick removing effect and feeling in use. CONSTITUTION: This cleaning agent for removing lipstick comprises 1-70wt.%, especially 2-50wt.% of an oil component based on the whole amount of a composition and a fatty acid monoethanolamide based surfactant of the formula (R is an alkyl; (n) is 1-8) as main components. R in the compound of the formula is preferably a 12-18C alkyl group which is general as a fatty acid residue. The amount of the compound of formula I mixed is 0.5-10.0wt.%, especially 1.0-5.0wt.% based on the whole amount of the composition. An ester oil such as cetyl-2-ethylhexanoate or dicapric acid neopentyl glycol and liquid paraffin are preferable as the oil component. The cleaning agent is basically a two layer type of an oil layer and a water layer, may be used as a uniform emulsion by light shaking in use or manufactured into a product as a solution of a substance by high shear treatment.
For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs. The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet. For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet. For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.    
The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:    
For adults and adolescents 15 years of age and older: one 10-mg tablet.    
For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.    
For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.    
Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.    
The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:    
For adults and adolescents 15 years of age and older: one 10-mg tablet.    
For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.    
For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established. who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time. Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.    
Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.
PURPOSE:To obtain a skin-beautifying cosmetic composition for curing or preventing the darkening of skin caused by ultraviolet ray or the pigmentation of skin such as spots and freckles by using an extract of a plant belonging to the family Compositae such as artichoke as an active component. CONSTITUTION:The active component to be used in the present composition is a substance extracted from a plant of the family Compositae and soluble in an organic solvent having medium polarity, a monohydric or polyhydric lower alcohol or their mixture. The skin-beautifying cosmetic is prepared by mixing the extract with arbitrary assistant components for cosmetic preparation such as activation agent, binder and diluent. The preferable amount of the active component depends upon the form of the cosmetic and the desired melanogenesis-suppressing effect, however, it is usually about 0.001-1.0%, more preferably about 0.01-0.5%. The composition may be further compounded with conventional melanogenesis-suppressing agent (e.g. vitamin C and placenta extract), ultraviolet scattering agent, ultraviolet absorber, anti-inflammatory agent, etc.
Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
Head and neck cancers rank as the sixth most prevalent cancers globally. In addition to traditional risk factors such as smoking and alcohol use, human papillomavirus (HPV) infections are becoming a significant causative agent of head and neck cancers, particularly among Western populations. Although HPV offers a significant survival benefit, the search for better biomarkers is still ongoing. In the current study, our objective was to investigate whether the expression levels of three PDZ-domain-containing proteins (SCRIB, NHERF2, and DLG1), known HPV E6 cellular substrates, influence the survival of HNSCC patients treated by primary surgery (n = 48). Samples were derived from oropharyngeal and oral cancers, and HPV presence was confirmed by PCR and p16 staining. Clinical and follow-up information was obtained from the hospital database and the Croatian Cancer registry up to November 2023. Survival was evaluated using the Kaplan-Meier method and Cox proportional hazard regression. The results were corroborated through the reanalysis of a comparable subset of TCGA cancer patients (n = 391). In conclusion, of the three targets studied, only SCRIB levels were found to be an independent predictor of survival in the Cox regression analysis, along with tumor stage. Further studies in a more typical Western population setting are needed since smoking and alcohol consumption are still prominent in the Croatian population, while the strongest association between survival and SCRIB levels was seen in HPV-negative cases.
The lithium-pilocarpine model is commonly used to recapitulate characteristics of human intractable focal epilepsy. In the current study, we explored the impact of topiramate (TPM) alone and in combination with pregabalin and lacosamide administration for 6 weeks on the evolution of spontaneous recurrent seizures (SRS) and disease-modifying potential on associated neuropsychiatric comorbidities. In addition, redox impairments and neurodegeneration in hippocampus regions vulnerable to temporal lobe epilepsy (TLE) were assessed by cresyl violet staining. Results revealed that acute electrophysiological (EEG) profiling of the ASD cocktail markedly halted sharp ictogenic spikes as well as altered dynamics of brain wave oscillations thus validating the need for polytherapy vs. monotherapy. In TLE animals, pharmacological intervention for 6 weeks with topiramate 10 mg/kg in combination with PREG and LAC at the dose of 20 mg/kg exhibited marked protection from SRS incidence, improved body weight, offensive aggression, anxiety-like behavior, cognitive impairments, and depressive-like behavior (p < 0.05). Moreover, combination therapy impeded redox impairments as evidenced by decreased MDA and AchE levels and increased activity of antioxidant SOD, GSH enzymes. Furthermore, polytherapy rescued animals from SE-induced neurodegeneration with increased neuronal density in CA1, CA3c, CA3ab, hilus, and granular cell layer (GCL) of the dentate gyrus. In conclusion, early polytherapy with topiramate in combination with pregabalin and lacosamide prompted synergy and prevented epileptogenesis with associated psychological and neuropathologic alterations.
PCT No. PCT/EP93/00932 Sec. 371 Date Jan. 17, 1995 Sec. 102(e) Date Jan. 17, 1995 PCT Filed Apr. 16, 1993 PCT Pub. No. WO93/20827 PCT Pub. Date Oct. 28, 1993The present invention is drawn to hyaluronic acid fractions having molecular weights in the range of from about 20,000 to about 60,000 daltons, wherein these hyaluronic acid fractions possess osteoinductive activity. The present invention further includes pharmaceutical compositions comprising such hyaluronic acid fractions to be used in the treatment of various types of bone disorders, as well as methods of treating such disorders using the pharmaceutical compositions.
Duchenne muscular dystrophy (DMD) is a devastating monogenic skeletal muscle-wasting disorder. Although many pharmacological and genetic interventions have been reported in preclinical studies, few have progressed to clinical trials with meaningful benefit. Identifying therapeutic potential can be limited by availability of suitable preclinical mouse models. More rigorous testing across models with varied background strains and mutations can identify treatments for clinical success. Here, we report the generation of a DMD mouse model with a CRISPR-induced deletion within exon 62 of the dystrophin gene (Dmd) and the first generated in BALB/c mice. Analysis of mice at 3, 6 and 12 months of age confirmed loss of expression of the dystrophin protein isoform Dp427 and resultant dystrophic pathology in limb muscles and the diaphragm, with evidence of centrally nucleated fibers, increased inflammatory markers and fibrosis, progressive decline in muscle function, and compromised trabecular bone development. The BALB/c.mdx62 mouse is a novel model of DMD with associated variations in the immune response and muscle phenotype, compared with those of existing models. It represents an important addition to the preclinical model toolbox for developing therapeutic strategies.
SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
Phenolic polymers are prepared by dissolving one or more organic phenols along with sodium periodate in aqueous base at pH 8-11, and allowing the mixtures to stand between 35 and 80° C. for a period of 30 minutes to 100 hours. One or more inorganic compounds or salts is added and the solution is allowed to stand at room temperature between 2 and 48 hours. Salt molecules as well as starting compounds and other low molecular-weight materials below about 500 to about 10,000 daltons are removed from the product solutions. Purified phenolic polymers are prepared in concentrated aqueous solution or in dried powder form in a final step if necessary. The resultant phenolic polymers exhibit physicochemical properties strongly resembling those of typical commercially-available natural soil extracts. The materials are active anti-viral and anti-microbial agents, and are effective in anti-viral amounts in blood product compositions, in methods for reducing or eliminating virus in blood products and in anti-viral and anti-microbial compositions for treating or preventing human or animal viral or microbial diseases.
Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
The invention provides a total alkaloid of common fibraurea stems, which contains palmatine hydrochloride with the weight percentage content over 60 percent and jatrorrhizine hydrochloride with the weight percentage content more than 10 percent. The invention also provides a method for preparing the total alkaloid of common fibraurea stems, fibriuretinin and jatrorrhizine. The method can be adopted to prepare the total alkaloid of common fibraurea stems and to extract separate fibriuretinin and jatrorrhizine, wherein if dry products are calculated on the basis of anhydrous palmatine hydrochloride (C21H22O4N.HCl), the fibriuretinin has the weight percentage content higher than 98.0 percent and is high in purity. The extraction-separation method enables the transfer rate of the palmatine hydrochloride to be up to over 26 percent and is 1.7 times higher than the prior conventional process (about 15 percent). The extraction process also maintains the jatrorrhizine while raising the transfer rate of the palmatine hydrochloride serving as a main component of the fibriuretinin, thereby greatly improving the resource utilization rate of medicinal materials. The process adopts a resin purification method, is simple and feasible in process flow, capable of regenerating and repeatedly utilizing resin and reducing environmental pollution caused by lye compared with the conventional salting-out method.
PURPOSE:The titled agent, containing a surfactant in the first agent composition and a cationic cellulosic derivative in the second agent composition, capable of applying an effective hair waving effect without damaging the hair, and giving good lasting waves. CONSTITUTION:A permanent waving agent containing the first agent composition containing 0.1-10.0(wt/vol)% surfactant selected from a anionic surfactant, e.g. sodium polyoxyethylene (10) lauryl ether phosphate, ampholytic surfactant, e.g. betaine lauryldimethylaminoacetate, and a nonionic surfactant, e.g. diethanolamide of coconut oil fatty acid and the second agent composition containing 0.1-5.0(wt/vol)% cationic cellulosic derivative in combination. EFFECT:Capable of giving the softness, gloss, smoothness and elasticity and further good feeling to the hair.
Given the limited options for treatments to improve the core symptoms of autism spectrum disorder (ASD), strategies that could target secondary features of the condition and improve quality of life for affected individuals are critical. Neuroplasticity-based cognitive training has been found to improve cognition in youth with attention deficit hyperactivity disorder (ADHD) and in adults with schizophrenia. In this trial, the investigators are seeking to extend the relevance of computerized cognitive training to youth with ASD. Given the literature, the investigators hypothesize that computerized cognitive training will produce gains in untrained cognitive tasks and behavioral ratings of executive functions in youth with ASD. The investigators will assess aspects of attention and executive functions in 30 affected youth and randomize them 1:1 to either neuroplasticity based cognitive tests or enjoyable age-appropriate computer games not intended to improve cognition. Cognition will be assessed again after 15 hours of training over 6 weeks and then again at a three month follow up.
This will be randomized controlled trial of 80-100 Gestational diabetic women of second trimester to investigate the effect of very low carbohydrate dietary intervention on glycemic, metabolic, glycated and inflammatory markers.

Subjects will be recruited from ob/gyn outpatient of different hospitals. Eligible subjects will be enrolled in the study and will be allocated into two groups. One will be intervention and other will be control group. At baseline fasting blood samples from both group will be taken and will be analyzed for different biomarkers. Thereafter, the experimental group will be counseled about their modified diet (very low carbohydrate diet \<10%,40-50% protein and lipid in diet). Control group will be allowed to continue their routine diet counselled as part of their antenatal care.
The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as “reproductive system related antigens,” and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
We recently demonstrated that transient attenuation of Toll-like receptor 4 (TLR4) in dorsal root ganglion (DRG) neurons, can both prevent and reverse pain associated with chemotherapy-induced peripheral neuropathy (CIPN), a severe side effect of cancer chemotherapy, for which treatment options are limited. Given the reduced efficacy of opioid analgesics to treat neuropathic, compared with inflammatory pain, the cross talk between nociceptor TLR4 and mu-opioid receptors (MORs), and that MOR and TLR4 agonists induce hyperalgesic priming (priming), which also occurs in CIPN, we determined, using male rats, whether (1) antisense knockdown of nociceptor MOR attenuates CIPN, (2) and attenuates the priming associated with CIPN, and (3) CIPN also produces opioid-induced hyperalgesia (OIH). We found that intrathecal MOR antisense prevents and reverses hyperalgesia induced by oxaliplatin and paclitaxel, two common clinical chemotherapy agents. Oxaliplatin-induced priming was also markedly attenuated by MOR antisense. Additionally, intradermal morphine, at a dose that does not affect nociceptive threshold in controls, exacerbates mechanical hyperalgesia (OIH) in rats with CIPN, suggesting the presence of OIH. This OIH associated with CIPN is inhibited by interventions that reverse Type II priming [the combination of an inhibitor of Src and mitogen-activated protein kinase (MAPK)], an MOR antagonist, as well as a TLR4 antagonist. Our findings support a role of nociceptor MOR in oxaliplatin-induced pain and priming. We propose that priming and OIH are central to the symptom burden in CIPN, contributing to its chronicity and the limited efficacy of opioid analgesics to treat neuropathic pain.
Epithelial Basement Membrane Dystrophy (EBMD) affects the anterior cornea, impacting about 2% of the population. EBMD is characterized by alterations and duplications of the basement membrane, a tissue layer that connects the epithelium to the underlying eye tissue. Dysfunction of the basement membrane prevents proper adhesion of the overlying epithelium, leading to recurrent corneal erosions. Additionally, tissue protrusions infiltrate the epithelium, creating surface irregularities that cause symptoms like blurred vision and irregular corneal topographies. This abnormal proliferation results in microcysts and corneal irregularities resembling fingerprints and maps. These surface irregularities can be observed in optical coherence tomography (OCT) images showing epithelial thickening. Non-invasive medical treatments are the first line of therapy, including lubricating drops and hypertonic solutions to protect the ocular surface and promote epithelial adhesion. For corneal erosions, soft contact lenses are used to aid healing. Surgical interventions such as manual debridement and phototherapeutic keratectomy (PTK) are required in refractory cases. These are also indicated for patients preparing for cataract surgery to optimize preoperative corneal measurements and postoperative optical outcomes. Manual debridement (MD), a technique since 1952, involves scraping off the irregular epithelium to allow a new layer to form. Some surgeons use 20% ethanol on the cornea before scraping with a blade or sponge, preserving the basement membrane. This method is simple, cost-effective, and has an 85% success rate in treating recurrent corneal erosions. However, recurrence rates are up to 24%, with the first recurrence typically within six months. Corneal opacities can form between 7 and 41 days post-procedure. Over the past two decades, PTK has become increasingly used for anterior corneal pathologies, including EBMD. PTK uses a 193nm excimer laser to break molecular bonds between cells on the epithelial surface. It is considered a more reliable, safe, and precise alternative to manual debridement, completely obliterating the basement membrane and potentially reducing recurrence rates. Success rates without recurrence range from 46% to 100%, with minimal complications. Unlike manual debridement, PTK may induce a hyperopic shift, which stabilizes within a year. Corneal erosions and pain recur at about 13% over an average of 9.7 months. Comparative studies between these two methods are scarce, and more data is needed to favor one technique over the other. Limited comparisons suggest PTK results are comparable to manual debridement, though shorter follow-ups in MD patients may underestimate associated complications. Our study aims to compare these techniques to describe the efficacy and safety of both treatments.
Method: This prospective multicentric observational cohort study enrolls participants of 75 years and over with symptomatic hip or knee OA for more than three months, hospitalized in seven geriatric departments of three hospitals of "Assistance Publique - Hôpitaux de Paris", for any cause of admission. Quality of care for OA before hospitalization is assessed by the Assessing Care of Vulnerable Elderly's (ACOVE) quality indicators (QI) for OA, using a questionnaire. The primary endpoint is the pass rate for the ACOVE's QI about referral to an orthopedic surgeon for patients with severe functionally compromising knee or hip OA. The secondary endpoints are the pass rates for the six others ACOVE's QI for OA (annual assessment of functional status and degree of pain ; exercise therapy for patients with newly diagnosed knee OA ; education regarding the natural history, treatment, and self- management of OA ; acetaminophen as first-line pharmacologic therapy ; advising patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) of their risks ; offering prophylaxis with a proton-pump inhibitor or misoprostol to patients treated with non-selective NSAIDs) and other elements of hip or knee OA care not assessed by the seven QI (including use of opioid analgesics, NSAIDs, intra-articular infiltrations, joint replacements). The sample is described with a rheumatologic assessment including Western Ontario and MACmaster universities osteoarthritis index (WOMAC) and Kellgren-Laurence classification, and with a geriatric assessment including nutritional status, Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scores, Mini Mental State Examination (MMSE) score, Timed Up and Go walking test, modified Short Emergency Geriatric Assessment (mSEGA) scale and Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Participants also complete the 12-Item Short Form Survey version 2 (SF-12v2) quality of life questionnaire. They receive a call twelve months after inclusion to collect vital status, orthopedic consultation and joint replacement during the last year.